rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 155 156 157 158 159 ... 179 »» | Laatste | Omlaag ↓
  2. [verwijderd] 15 oktober 2007 19:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    dat valt wel mee, tis wachten op start fase III oralin, als het goed is voor 21 december (herfst), aldus gnbt....
    Dan gaan we vet omhoog...
  7. [verwijderd] 16 oktober 2007 16:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De geschiedenis herhaalt zich... precies hetzelfde als een jaar geleden alleen nu andere contractors...
    En het is nog een purchase deal ook...

    Z W E N D E L

    Generex Biotechnology Appoints Leading Contract Research Organization To Manage Global Phase III trials for Generex Oral-lyn (TM)

    Company Also Selects Other Key Service Providers to Support Upcoming Site Selection and Patient Enrollment

    Worcester, MA - October 15, 2007 – Generex Biotechnology Corporation (NasdaqCM:GNBT) , the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has engaged and entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn™, its proprietary oral insulin spray product. Generex has selected PSI-CRO AG Clinical Research Services (“PSI”) (www.psi-cro.com), a leading contract drug development company to serve as the company's global clinical research organization (CRO), to provide full-service CRO services with 600-full-time staff in Europe and North America.

    Another key service provider selected and engaged by the company is Nextrials, Inc.( www.nextrials.com), which will be responsible for providing Electronic Data Capture, randomization and data management services. Nextrials is an innovative, award-winning, leader in web-based software solutions for the clinical research industry. Generex has also entered into an agreement with eResearchTechnology, Inc. (NASDAQ: ERES), (www.ert.com) a market leader in providing centralized electrocardiographic (diagnostic) and cardiac safety services to supply equipment and provide central ECG services for the Company's Phase III trial. Negotiations with other key service providers and suppliers are ongoing and expected to be completed very soon.



    The Company has procured each of these service providers through the efforts of OSMOS Clinical Research, Inc. (www.osmos.us) of San Francisco, California which Generex engaged earlier this year to assist the Company with the global project management of the Phase III clinical trial.



    The Phase III global multi-center clinical study, where enrollment is anticipated to commence shortly, is expected to include 750 patients with Type 1 diabetes mellitus. The primary objective of the study is to compare the efficacy of Generex Oral-lyn (TM) and the RapidMist (TM) Diabetes Management Sytem with that of standard regular injectable human insulin therapy as measured by HbA1c, in patients with Type-1 diabetes mellitus.



    “We are pleased at the progress the Company has made in securing quality service providers as we prepare to announce trial site locations and commence enrollment ,” said Anna Gluskin, Generex's President and Chief Executive Officer. "We believe this study will demonstrate the success that other Type 1 and Type 2 patients have already experienced internationally and will pave the way for commercialization of Generex Oral-lyn™ in North America.”
  10. [verwijderd] 16 oktober 2007 20:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    “We are pleased at the progress the Company has made in securing quality service providers as we prepare to announce trial site locations and commence enrollment ,” said Anna Gluskin

    start Fase III is dus aanstaande !

    let ,maar eens op wat de koers dan gaat doen ...

    1.50 is bodem, daaronder valt niet meer veel te halen voor drukkers.
  21. [verwijderd] 18 oktober 2007 15:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Announces Product Licensing & Distribution Agreement For Generex Oral-lyn™ in South Africa

    Adcock Ingram Healthcare (Pty) Ltd. to market and distribute Generex Oral-lyn in
    South Africa and six other neighboring countries




    whoooooooeeeeeeeeeeeeeee!!!

    Oral-Lyn en AdCock!!!!! je bedenkt het niet....hahahahaha
3.572 Posts
Pagina: «« 1 ... 155 156 157 158 159 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.658
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.654
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.841
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.845
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.215
AMG 971 133.343
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.999
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.709
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.102
ASML 1.766 107.265
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392